ESLA – estrella immunopharma, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

ESLA

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/4

08:00 am

esla

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Medium Report

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Report

11/22

02:11 am

esla

Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at Wall Str

High Report

Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at Wall Str

Report

11/22

02:11 am

esla

Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at Wall Str

High Report

Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at Wall Str

Report

11/3

11:24 am

esla

Estrella Immunopharma (NASDAQ:ESLA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.

High Report

Estrella Immunopharma (NASDAQ:ESLA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.

Report

11/3

08:00 am

esla

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Medium Report

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Report

10/31

01:02 pm

esla

Estrella Immunopharma (NASDAQ:ESLA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Low Report

Estrella Immunopharma (NASDAQ:ESLA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Report

10/6

08:20 am

esla

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements [Yahoo! Finance]

High Report

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements [Yahoo! Finance]

Report

10/6

08:00 am

esla

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

High Report

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Report

10/3

03:35 pm

esla

Estrella Immunopharma (NASDAQ:ESLA) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Low Report

Estrella Immunopharma (NASDAQ:ESLA) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.